Live
10x Genomics BlogIs It Too Late To Consider 10x Genomics (TXG) After Its 185% One-Year Surge? - simplywall.stThermo FisherThermo Fisher Scientific and PRECISE Partner on Singapore Proteomics Study - Clinical Lab ProductsEndpoints NewsFDA asks for more data on Lilly’s Foundayo to assess heart, liver risksEndpoints NewsReplimune looks ahead as repeat CRL speeds the company's declineBioPharma DiveTravere wins long-awaited approval for kidney disease drugFierceBiotechAustralia’s Kazia pays research institute $1.4M for epigenetic platform, preclinical drugFierceBiotechNovo taps OpenAI to deploy AI across R&D, manufacturing and corporate functionsFierceBiotechClick Therapeutics cuts staff after commercial deal restructuringFierceBiotechAstellas to close stem cell unit’s Seattle site, with layoffs incomingFierceBiotechCell therapy biotech Obsidian leverages Galera reverse merger to go publicBioWorldBiologics in development outnumber small molecules for the first timeBioWorldEverest to acquire Singapore unit of Hasten Bio in $250M deal
BioPharma Dive Apr 14, 2026

J&J leans on Tremfya, cancer drugs to overcome Stelara losses

J&J leans on Tremfya, cancer drugs to overcome Stelara losses

Original
Body unavailable. Use the original source.

Directory

59 All